Share ownership argenx SE

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-04-15 EDT			5-day change	1st Jan Change
710.00 ^EUR	+0.71%		+5.88%	-0.95%

04-15	European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading	MT
04-15	ARGENX : Goldman Sachs keeps its Buy rating	ZD

Share class: argenx SE

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	60,760,957	60,295,150 ( 99.23 %)	0	99.23 %

Major shareholders: argenx SE

Name	Equities	%	Valuation
Norges Bank Investment Management 2.774 %	1,716,514	2.774 %	1 228 M €
FMR Investment Management (UK) Ltd. 0.1771 %	109,565	0.1771 %	78 M €
Sjunde AP-fonden 0.1429 %	88,442	0.1429 %	63 M €
State Street Global Advisors Ltd. 0.1248 %	77,231	0.1248 %	55 M €
Tim van Hauwermeiren 0.1165 %	72,096	0.1165 %	52 M €
Lazard Asset Management Ltd. 0.0947 %	58,587	0.0947 %	42 M €
HBM Partners AG (Investment Management) 0.0848 %	52,500	0.0848 %	38 M €
Storebrand Asset Management AS 0.0648 %	40,070	0.0648 %	29 M €
Fineco Asset Management DAC 0.0625 %	38,672	0.0625 %	28 M €
OFI Invest Asset Management SA 0.0521 %	32,219	0.0521 %	23 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 9.037 %	5,592,319	9.037 %	4 084 M €
T. Rowe Price International Ltd. 5.433 %	3,362,324	5.433 %	2 455 M €
Janus Henderson Investors US LLC 3.972 %	2,458,164	3.972 %	1 795 M €
Capital Research & Management Co. (World Investors) 3.097 %	1,916,234	3.097 %	1 399 M €
Artisan Partners Holdings LP 2.839 %	1,756,942	2.839 %	1 283 M €
Avoro Capital Advisor LLC 1.6 %	990,000	1.6 %	723 M €
Wellington Trust Co., NA 1.098 %	679,236	1.098 %	496 M €
RTW Investments LP 1.088 %	673,497	1.088 %	492 M €
BlackRock Advisors LLC 0.8724 %	539,848	0.8724 %	394 M €
Eaton Vance Management 0.8384 %	518,852	0.8384 %	379 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	46.34%
Other	6.01%
SEI Investments Co.	0.54%
Individuals	0.18%
Manulife Financial Corp.	0.09%
State Street Corp.	0.01%
Unknown	46.83%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	38.5%
United Kingdom	7.15%
Norway	2.87%
Switzerland	0.98%
Canada	0.85%
France	0.55%
Ireland	0.46%
Sweden	0.27%
Germany	0.27%
Luxembourg	0.21%
Individuals	0.18%
Belgium	0.11%
Japan	0.11%
Netherlands	0.1%
Australia	0.09%
Cayman Islands	0.08%
Italy	0.08%
Spain	0.06%
Austria	0.06%
Taiwan	0.04%
Denmark	0.03%
Hong Kong	0.02%
Finland	0.02%
Singapore	0.02%
China	0.01%
Mexico	0.01%
South Africa	0.01%
New Zealand	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,863

Sector

Biotechnology & Medical Research

Calendar

05-07 - Earnings release - Q1 2026

More about the company